Onderzoeksoutput per jaar
Onderzoeksoutput per jaar
- 20 resultaten
Zoekresultaten
-
2022
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB)
Schwarze, J. K., Geens, W., Tijtgat, J., Awada, G., Vanbinst, A., Everaert, H., Seynaeve, L., Michotte, A., Bruneau, M., VAN RIET, I., Tuyaerts, S., Duerinck, J. & Neyns, B., 3 jun. 2022.Onderzoeksoutput: Poster
-
A phase I clinical trial on the intracranial administration of increasing doses of ipilimumab plus fixed dose nivolumab in patients with recurrent glioblastoma (rGB).
Geens, W., Schwarze, J. K., Tijtgat, J., Lescrauwaet, L. C., Tuyaerts, S., Geeraerts, X., Stevens, L., Vanbinst, A., Everaert, H., Bruneau, M., Duerinck, J. & Neyns, B., 2022.Onderzoeksoutput: Poster
-
Early interim results from a randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in non-small cell lung cancer (NSCLC)
Tijtgat, J., Schwarze, J. K., Vandenbroucke, F., Ilsen, B., Tuyaerts, S., Dufait, I., Decoster, L., De Ridder, M. & Neyns, B., 22 sep. 2022.Onderzoeksoutput: Poster
-
Repeated intracranial administration of ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB): A multi-cohort adaptive phase I clinical trial
Geens, W., Schwarze, J. K., Tijtgat, J., Lescrauwaet, L. C., Geeraerts, X., Vaeyens, F., Vanbinst, A., Everaert, H., Michotte, A., Cauwenbergh, T., Bruneau, M., Tuyaerts, S., Neyns, B. & Duerinck, J., 5 sep. 2022, blz. ii38-ii39.Onderzoeksoutput: Poster
-
-
2021
371P - Low-dose bevacizumab for the treatment of focal post-radiation necrosis of the brain
Tijtgat, J., Schwarze, J. K. & Awada, G., 16 sep. 2021.Onderzoeksoutput: Poster
-
S1-28 The oncolytic HSV-1 virus T-VEC induces immunogenic cell death of melanoma cells and efficiently matures monocyte derived as well as BDCA-1+/BDCA-3+ myeloid dendritic cells
De Munck, J., Kalus, P., Smets, H., Broos, K., Tijtgat, J., Van Riet, I., Dufait, I., Schwarze, J. K., Goyvaerts, C., Neyns, B., Tuyaerts, S., Breckpot, K. & Aerts, J., 10 mei 2021.Onderzoeksoutput: Poster
-
S2-106 Talimogene laherparepvec (T-VEC)-induced tumor oncolysate as a source of tumor antigens and maturation factors for blood-isolated myeloid dendritic cells
Tijtgat, J., De Munck, J., Dufait, I., Schwarze, J. K., Breckpot, K., Neyns, B., Aerts, J. & Tuyaerts, S., 11 mei 2021.Onderzoeksoutput: Poster
Bestand18 Downloads (Pure) -
2020
A phase I clinical trial on intratumoral and intracavitary administration of ipilimumab and nivolumab in patients with recurrent glioblastoma: Brussel Poster presentation on Glitipni-study at ASCO Annual Meeting 2020; May 29 - June 2, 2020; virtual
Schwarze, J. K., Duerinck, J., Dufait, I., Awada, G., Klein, S., Fischbuch, L., Seynaeve, L., Vaeyens, F., Rogiers, A., Everaert, H., Vanbinst, A., Michotte, A. & Neyns, B., 2020.Onderzoeksoutput: Poster
-
High total metabolic tumor volume on 18F-FDG-PET/CT correlates with lack of immune response in advanced melanoma patients treated with pembrolizumab.
Gondry, O., Awada, G., Özdemir, I., Schwarze, J. K., Daeninck, E., Jansen, Y., Seremet, T., Goethals, L., Everaert, H., Neyns, B. & Keyaerts, M., 15 jan. 2020, (Unpublished).Onderzoeksoutput: Poster
-
Interim safety and efficacy results of a phase II clinical trial on trametinib and low-dose dabrafenib in patients with advanced BRAFV600 wild-type melanoma
Awada, G., Schwarze, J. K., Reijmen, E., Goyvaerts, C., Fasolino, G., Aspeslagh, S. & Neyns, B., 2020.Onderzoeksoutput: Poster
Bestand35 Downloads (Pure) -
2019
A sequential dual cohort phase II clinical trial on adjuvant low-dose nivolumab with or without low-dose ipilimumab as adjuvant therapy following the resection of melanoma macrometastases (MM)
Schwarze, J. K., Vandersleyen, V., Awada, G., Seremet, T., Jansen, Y. & Neyns, B., 2019.Onderzoeksoutput: Poster
-
GLIAVAX: A stratified phase II clinical trial of avelumab and axitinib in patients with recurrent glioblastoma.
Neyns, B., Ben Salama, L., Awada, G., De Cremer, J., Schwarze, J. K., Seynaeve, L., Du Four, S., Fischbuch, L., Vanbinst, A-M., Everaert, H., Michotte, A., Rogiers, A. I., Theuns, P. & Duerinck, J., 2019.Onderzoeksoutput: Poster
-
-
2018
A phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors
Schwarze, J. K., Awada, G., Van Riet, I. & Neyns, B., 14 dec. 2018.Onderzoeksoutput: Poster
-
Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab
Awada, G., Özdemir, I., Schwarze, J. K., Daeninck, E., Gondry, O., Jansen, Y., Caplanusi, T., Keyaerts, M., Everaert, H. & Neyns, B., 13 dec. 2018.Onderzoeksoutput: Poster
-
2016
Auranofin radiosensitizes tumor cells through enhanced production of reactive oxygen species
Wang, H., Bouzakoura, S., Jiang, H., Schwarze, J. K., Law Ka, L., Dufait, I., Verovski, V. N., Van den Berge, D. & De Ridder, M., 2016.Onderzoeksoutput: Poster
-
2015
EX VIVO GENERATION OF MDSC THAT MODEL THE TUMOR IMMUNOSUPPRESSIVE ENVIRONMENT IN COLORECTAL CANCER
Dufait, I., Schwarze, J. K., Liechtenstein, T., Leonard, W., Jiang, H., Verovski, V. N., Escors, D., De Ridder, M. & Breckpot, K., 31 mrt. 2015.Onderzoeksoutput: Poster
-
2014
DIFFERENTIATION OF MYELOID-DERIVED SUPPRESSOR CELLS FROM BONE MARROW USING CONDITIONED MEDIA FROM LENTIVIRAL-MODIFIED COLORECTAL CANCER CELLS
Dufait, I., Liechtenstein, T., Schwarze, J. K., Leonard, W., Verovski, V. N., Escors, D., De Ridder, M. & Breckpot, K., 1 apr. 2014.Onderzoeksoutput: Poster
-
Differentiation of myeloid-derived suppressor cells from bone marrow using conditioned media from LV-modified colorectal cancer cells
Dufait, I., Liechtenstein, T., Schwarze, J. K., Leonard, W., Verovski, V. N., Escors, D., De Ridder, M. & Breckpot, K., 18 apr. 2014.Onderzoeksoutput: Poster